Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 801-802

  Lee, S C ^a   Kim, S J ^b   Lee, D H ^c   Kim, W S ^b   Suh, C ^c   Won, J H ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; MELPHALAN; THIOTEPA;

ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; LETTER; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; THROMBOCYTE COUNT;

ADULT; BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 77950627286     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.240     Document Type: Letter

References (8)

1. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476. (Pubitemid 35174820)
2. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672-684. (Pubitemid 351664062)
3. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/ cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493-500.
4. Bensinger WI, Schiffman KS, Holmberg L, Appelbaum FR, Maziarz R, Montgomery P et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplant 1997; 19: 1183-1189. (Pubitemid 27302727)
5. Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651-659. (Pubitemid 28486363)
6. Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261-266. (Pubitemid 127530484)
7. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306-315.
8. Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D et al. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008; 49: 1899-1906.